LIVIVO - Search results -

Search results

Result 1 - 10 of total 43

Search options

Article ; Online: Age-related macular degeneration: a review of current therapies and new treatments.

Kniggendorf, Vinicius / Dreyfuss, Juliana L / Regatieri, Caio V

2020 Volume 83, Issue 6, Page(s) 552–561

Abstract: Age-related macular degeneration is the leading cause of vision loss in elderly individuals, as well as a medical and socio-economic challenge. The treatment of dry age-related macular degeneration is based on vitamin supplementation. New treatment ... ...

Abstract	Age-related macular degeneration is the leading cause of vision loss in elderly individuals, as well as a medical and socio-economic challenge. The treatment of dry age-related macular degeneration is based on vitamin supplementation. New treatment studies are focused on preventing the progression of degeneration and repopulating the atrophic macula. Recently, research on the treatment of neovascular age-related macular degeneration experienced a breakthrough with the advent of anti-vascular endothelial growth factor inhibitors. Nevertheless, despite the fact that ranibizumab, aflibercept, and bevacizumab are effective in reducing severe visual impairment, patients usually lose some vision over time. Therefore, the search for new therapies and diagnostic methods is fundamentally important. Current studies are focused on new anti-vascular endothelial growth factor drugs, nucleoside reverse transcriptase inhibitors, antibody against sphingosine-1-phosphate, anti-platelet-derived growth factor, gene therapy, and RNA interference. The results of ongoing clinical studies may improve the therapy of age-related macular degeneration.
MeSH term(s)	Aged ; Angiogenesis Inhibitors/therapeutic use ; Bevacizumab/therapeutic use ; Humans ; Intravitreal Injections ; Macular Degeneration/drug therapy ; Ranibizumab/therapeutic use ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Recombinant Fusion Proteins/therapeutic use ; Vascular Endothelial Growth Factor A ; Visual Acuity
Chemical Substances	Angiogenesis Inhibitors ; Recombinant Fusion Proteins ; Vascular Endothelial Growth Factor A ; Bevacizumab (2S9ZZM9Q9V) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; Ranibizumab (ZL1R02VT79)
Language	English
Publishing date	2020-08-12
Publishing country	Brazil
Document type	Journal Article ; Review
ZDB-ID	603915-7
ISSN	1678-2925 ; 0004-2749
ISSN (online)	1678-2925
ISSN	0004-2749
DOI	10.5935/0004-2749.20200082
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 503: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 317: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Challenges and advantages of being a scientific journal editor in the era of ChatGPT.

Lira, Rodrigo Pessoa Cavalcanti / Rocha, Eduardo Melani / Kara-Junior, Newton / Costa, Dácio Carvalho / Procianoy, Fernando / Paula, Jayter Silva de / Gracitelli, Carolina P B / Prata, Tiago da Silva / Regatieri, Caio V / Biccas Neto, Laurentino / Alves, Monica

Arquivos brasileiros de oftalmologia

2023 Volume 86, Issue 3, Page(s) 5–7

Language	English
Publishing date	2023-06-02
Publishing country	Brazil
Document type	Editorial
ZDB-ID	603915-7
ISSN	1678-2925 ; 0004-2749
ISSN (online)	1678-2925
ISSN	0004-2749
DOI	10.5935/0004-2749.2023-1003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 503: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 317: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: New anti-angiogenic compound based on chemically modified heparin.

Kniggendorf, Vinicius / Souza, Maria Eduarda Perrud / Russo, Thatiane / de Lima, Marcelo Andrade / Grupenmacher, Alex Treiger / Regatieri, Caio V / Dreyfuss, Juliana L

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

2022 Volume 260, Issue 12, Page(s) 3847–3855

Abstract: Purpose: The purpose of this study was to measure the anti-angiogenic effect of N-desulfated Re-N-acetylated, a chemically modified heparin (mHep).: Methods: In vitro assays (cell tube formation, viability, proliferation, and migration) with ... ...

Abstract	Purpose: The purpose of this study was to measure the anti-angiogenic effect of N-desulfated Re-N-acetylated, a chemically modified heparin (mHep). Methods: In vitro assays (cell tube formation, viability, proliferation, and migration) with endothelial cells were performed after 24 h of treatment with mHep at 10, 100, and 1000 ng/mL or saline. In vivo tests were performed after laser-induced choroidal neovascularization (CNV) in rats, followed by an intravitreal injection (5 µL) of mHep (10, 100, 1000 ng/mL) or balanced salt solution. Immunofluorescence analysis of the CNV was performed after 14 days. Results: mHep produced a statistically significant reduction in cell proliferation, tube formation, and migration, without cell viability changes when compared to saline. Mean measures of CNV area were 54.84 × 10 Conclusions: These results suggest that mHep N-DRN is a potent anti-angiogenic, anti-proliferative, and anti-migratory compound with negligible anticoagulant or hemorrhagic action and no cytotoxicity for retina cells. This compound may serve as a candidate for treating choroidal neovascularization.
MeSH term(s)	Rats ; Animals ; Mice ; Choroidal Neovascularization/drug therapy ; Fluorescein Angiography ; Endothelial Cells ; Heparin/pharmacology ; Heparin/therapeutic use ; Angiogenesis Inhibitors/pharmacology ; Angiogenesis Inhibitors/therapeutic use ; Disease Models, Animal ; Mice, Inbred C57BL
Chemical Substances	Heparin (9005-49-6) ; Angiogenesis Inhibitors
Language	English
Publishing date	2022-09-13
Publishing country	Germany
Document type	Journal Article
ZDB-ID	8435-9
ISSN	1435-702X ; 0721-832X
ISSN (online)	1435-702X
ISSN	0721-832X
DOI	10.1007/s00417-022-05828-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ul I Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Artificial intelligence in uveitis: A comprehensive review.

Nakayama, Luis F / Ribeiro, Lucas Z / Dychiao, Robyn G / Zamora, Yuslay F / Regatieri, Caio V S / Celi, Leo A / Silva, Paolo / Sobrin, Lucia / Belfort, Rubens

Survey of ophthalmology

2023 Volume 68, Issue 4, Page(s) 669–677

Abstract: Uveitis is a disease complex characterized by intraocular inflammation of the uvea that is an important cause of blindness and social morbidity. With the dawn of artificial intelligence (AI) and machine learning integration in health care, their ... ...

Abstract	Uveitis is a disease complex characterized by intraocular inflammation of the uvea that is an important cause of blindness and social morbidity. With the dawn of artificial intelligence (AI) and machine learning integration in health care, their application in uveitis creates an avenue to improve screening and diagnosis. Our review identified the use of artificial intelligence in studies of uveitis and classified them as diagnosis support, finding detection, screening, and standardization of uveitis nomenclature. The overall performance of models is poor, with limited datasets and a lack of validation studies and publicly available data and codes. We conclude that AI holds great promise to assist with the diagnosis and detection of ocular findings of uveitis, but further studies and large representative datasets are needed to guarantee generalizability and fairness.
MeSH term(s)	Humans ; Artificial Intelligence ; Machine Learning ; Uveitis/diagnosis ; Delivery of Health Care ; Uvea
Language	English
Publishing date	2023-03-04
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	391346-6
ISSN	1879-3304 ; 0039-6257
ISSN (online)	1879-3304
ISSN	0039-6257
DOI	10.1016/j.survophthal.2023.02.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 283: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Ocular Angiogenesis.

Dreyfuss, Juliana L / Giordano, Ricardo J / Regatieri, Caio V

Journal of ophthalmology

2015 Volume 2015, Page(s) 892043

Language	English
Publishing date	2015-09-28
Publishing country	United States
Document type	Journal Article
ZDB-ID	2546525-9
ISSN	2090-0058 ; 2090-004X
ISSN (online)	2090-0058
ISSN	2090-004X
DOI	10.1155/2015/892043
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Bilateral macular hole after anti-vascular endothelial growth factor therapy in a patient with exudative age-related macular degeneration.

Regatieri, Caio V / Duker, Jay S

Retinal cases & brief reports

2012 Volume 6, Issue 1, Page(s) 125–128

Abstract: Purpose: To report a case of bilateral nonsequential macular holes that developed after intravitreal ranibizumab therapy for treatment of exudative age-related macular degeneration.: Methods: A 76-year-old man presented with sudden vision loss in the ...

Abstract	Purpose: To report a case of bilateral nonsequential macular holes that developed after intravitreal ranibizumab therapy for treatment of exudative age-related macular degeneration. Methods: A 76-year-old man presented with sudden vision loss in the right eye initially followed by the left eye 1 year later. Initial fundoscopic examination showed a subretinal hemorrhage in the right eye and dry macular degeneration in the left eye. Initial optical coherence tomography and fluorescein angiogram confirmed the diagnosis of subfoveal choroidal neovascularization in the right eye. There was no evidence of vitreofoveal traction. The patient was treated with intravitreal injections of ranibizumab (0.5 mg). One year later, choroidal neovascularization developed in his left eye as well. Results: After choroidal neovascularization regression, full-thickness macular holes were observed in both eyes. Pars plana vitrectomy with internal limiting membrane removal was performed in both eyes. Anatomic closure of the macular hole in the left eye without significant vision improvement occurred but the right macular hole remained open despite the surgery. Conclusion: Exudative age-related macular degeneration can be a precursor to macular hole formation.
Language	English
Publishing date	2012
Publishing country	United States
Document type	Journal Article
ISSN	1935-1089
ISSN	1935-1089
DOI	10.1097/ICB.0b013e3182160952
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Advances in Retinal Tissue Engineering.

Trese, Matthew / Regatieri, Caio V / Young, Michael J

Materials (Basel, Switzerland)

2012 Volume 5, Issue 1, Page(s) 108–120

Abstract: Retinal degenerations cause permanent visual loss and affect millions world-wide. Current treatment strategies, such as gene therapy and anti-angiogenic drugs, merely delay disease progression. Research is underway which aims to regenerate the diseased ... ...

Abstract	Retinal degenerations cause permanent visual loss and affect millions world-wide. Current treatment strategies, such as gene therapy and anti-angiogenic drugs, merely delay disease progression. Research is underway which aims to regenerate the diseased retina by transplanting a variety of cell types, including embryonic stem cells, fetal cells, progenitor cells and induced pluripotent stem cells. Initial retinal transplantation studies injected stem and progenitor cells into the vitreous or subretinal space with the hope that these donor cells would migrate to the site of retinal degeneration, integrate within the host retina and restore functional vision. Despite promising outcomes, these studies showed that the bolus injection technique gave rise to poorly localized tissue grafts. Subsequently, retinal tissue engineers have drawn upon the success of bone, cartilage and vasculature tissue engineering by employing a polymeric tissue engineering approach. This review will describe the evolution of retinal tissue engineering to date, with particular emphasis on the types of polymers that have routinely been used in recent investigations. Further, this review will show that the field of retinal tissue engineering will require new types of materials and fabrication techniques that optimize the survival, differentiation and delivery of retinal transplant cells.
Language	English
Publishing date	2012-01-05
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2487261-1
ISSN	1996-1944
ISSN	1996-1944
DOI	10.3390/ma5010108
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration.

Regatieri, Caio V / Branchini, Lauren / Duker, Jay S

Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye

2011 Volume 42 Suppl, Page(s) S56–66

Abstract: Spectral-domain optical coherence tomography (SD-OCT) has emerged as the ancillary examination of choice to assist the diagnosis and management of neovascular age-related macular degeneration (AMD). SD-OCT provides more detailed images of intraretinal, ... ...

Abstract	Spectral-domain optical coherence tomography (SD-OCT) has emerged as the ancillary examination of choice to assist the diagnosis and management of neovascular age-related macular degeneration (AMD). SD-OCT provides more detailed images of intraretinal, subretinal, and subretinal pigment epithelium fluid when compared to time-domain technology, leading to higher and earlier detection rates of neovascular AMD activity. Improvements in image analysis and acquisition speed make it important for decision-making in the diagnosis and treatment of this disease. However, this new technology needs to be validated for its role in the improvement of visual outcomes in the context of anti-angiogenic therapy.
MeSH term(s)	Diagnostic Techniques, Ophthalmological ; Humans ; Tomography, Optical Coherence ; Visual Acuity/physiology ; Wet Macular Degeneration/diagnosis ; Wet Macular Degeneration/therapy
Language	English
Publishing date	2011-07-26
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S. ; Review
ZDB-ID	2101552-1
ISSN	1938-2375 ; 1082-3069 ; 1542-8877
ISSN (online)	1938-2375
ISSN	1082-3069 ; 1542-8877
DOI	10.3928/15428877-20110627-05
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 756: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Retinal and choroidal angiogenesis: a review of new targets.

Cabral, Thiago / Mello, Luiz Guilherme M / Lima, Luiz H / Polido, Júlia / Regatieri, Caio V / Belfort, Rubens / Mahajan, Vinit B

International journal of retina and vitreous

2017 Volume 3, Page(s) 31

Abstract: Retinal and choroidal neovascularization are a major cause of significant visual impairment, worldwide. Understanding the various factors involved in the accompanying physiopathology is vital for development of novel treatments, and most important, for ... ...

Abstract	Retinal and choroidal neovascularization are a major cause of significant visual impairment, worldwide. Understanding the various factors involved in the accompanying physiopathology is vital for development of novel treatments, and most important, for preserving patient vision. The intraocular use of anti-vascular endothelial growth factor therapeutics has improved management of the retinal and choroidal neovascularization but some patients do not respond, suggesting other vascular mediators may also contribute to ocular angiogenesis. Several recent studies examined possible new targets for future anti-angiogenic therapies. Potential targets of retinal and choroidal neovascularization therapy include members of the platelet-derived growth factor family, vascular endothelial growth factor sub-family, epidermal growth factor family, fibroblast growth factor family, transforming growth factor-β superfamily (TGF-β1, activins, follistatin and bone morphogenetic proteins), angiopoietin-like family, galectins family, integrin superfamily, as well as pigment epithelium derived factor, hepatocyte growth factor, angiopoietins, endothelins, hypoxia-inducible factors, insulin-like growth factors, cytokines, matrix metalloproteinases and their inhibitors and glycosylation proteins. This review highlights current antiangiogenic therapies under development, and discusses future retinal and choroidal pro- and anti-angiogenic targets as wells as the importance of developing of new drugs.
Language	English
Publishing date	2017-08-21
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2836254-8
ISSN	2056-9920
ISSN	2056-9920
DOI	10.1186/s40942-017-0084-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration.

Cabral, Thiago / Lima, Luiz H / Polido, Júlia / Duong, Jimmy / Okuda, Érika / Oshima, Akiyoshi / Serracarbassa, Pedro / Regatieri, Caio V / Belfort, Rubens

International journal of retina and vitreous

2017 Volume 3, Page(s) 6

Abstract: Purpose: To evaluate the concentration of vascular endothelial growth factor (VEGF) in aqueous humor after a single intravitreal injection of bevacizumab (IVB) in eyes with neovascular age-related macular degeneration (AMD).: Methods: In this ... ...

Abstract	Purpose: To evaluate the concentration of vascular endothelial growth factor (VEGF) in aqueous humor after a single intravitreal injection of bevacizumab (IVB) in eyes with neovascular age-related macular degeneration (AMD). Methods: In this prospective interventional case series study, 24 eyes of 24 patients with types 1 and 2 choroidal neovascularization secondary to neovascular AMD were treated with a single intravitreal injection of bevacizumab. Aqueous humor samples were obtained before the intravitreal injection and at one week, one month, and three months follow-up periods. Best-corrected visual acuity (BCVA) and three spectral-domain optical coherence tomography parameters (central retinal thickness, macular volume and macular area) were also analyzed and correlated with VEGF expression at the baseline and each follow-up period. Results: All of the ninety-six aqueous humor study taps were well tolerated by the study patients without adverse events. Increased VEGF levels (mean ± SD = 179.7 ± 88.3 pg/mL) were observed in the aqueous humor of all study patients before the intravitreal injection of bevacizumab. At all follow-up periods, compared to baseline, levels of VEGF significantly reduced (P < 0.0001), and BCVA significantly improved (P < 0.005). The lowest VEGF expression was observed at 1 week, and the greatest BCVA improvement occurred 1 month after treatment. At 1 month, central retinal thickness (CRT), macular volume (MV), and macular area (MA) significantly reduced compared to baseline (P < 0.0001, P = 0.0005, P = 0.007, P = 0.009, respectively). At 1 week and 3 months, although without statistical significance (P > 0.005), CRT, MV and MA also reduced in comparison to baseline. Conclusions: Single intravitreal bevacizumab injection in eyes with neovascular AMD resulted in a substantial decrease of aqueous VEGF levels 1 week after treatment with the greatest improvement of clinical outcomes occurring at 1 month follow-up.
Language	English
Publishing date	2017-05-01
Publishing country	England
Document type	Journal Article
ZDB-ID	2836254-8
ISSN	2056-9920
ISSN	2056-9920
DOI	10.1186/s40942-017-0066-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito